While Teva- Pharmaceutical Industries Ltd. ADR has underperformed by -0.44%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TEVA rose by 34.94%, with highs and lows ranging from $13.56 to $7.09, whereas the simple moving average jumped by 39.62% in the last 200 days.
On February 12, 2024, Piper Sandler Upgraded Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) to Overweight. A report published by Jefferies on January 23, 2024, Upgraded its rating to ‘Buy’ for TEVA. Piper Sandler also Upgraded TEVA shares as ‘Neutral’, setting a target price of $12 on the company’s shares in a report dated January 03, 2024. HSBC Securities Initiated an Buy rating on December 18, 2023, and assigned a price target of $13. UBS November 27, 2023d its ‘Neutral’ rating to ‘Buy’ for TEVA, as published in its report on November 27, 2023. UBS’s report from July 06, 2023 suggests a price prediction of $8 for TEVA shares, giving the stock a ‘Neutral’ rating. Morgan Stanley also rated the stock as ‘Equal-Weight’.
Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Further, the quarter-over-quarter increase in sales is 13.52%, showing a positive trend in the upcoming months.
Teva- Pharmaceutical Industries Ltd. ADR’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -7.27% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.69, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and TEVA has an average volume of 10.58M. On a monthly basis, the volatility of the stock is set at 2.59%, whereas on a weekly basis, it is put at 2.43%, with a gain of 1.13% over the past seven days. Furthermore, long-term investors anticipate a median target price of $15.25, showing growth from the present price of $13.44, which can serve as yet another indication of whether TEVA is worth investing in or should be passed over.
How Do You Analyze Teva- Pharmaceutical Industries Ltd. ADR Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.01%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 52.45% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TEVA shares are owned by institutional investors to the tune of 52.45% at present.
